AstraZeneca has announced the launch of Evinova, a separate health-tech business focused on offering its knowledge of clinical trial design and study delivery. This move will provide solutions at scale to trial sponsors, clinical-research organizations, care teams, and patients. The goal is to reduce the time and cost of developing new medicines, bring care closer to home for patients, and reduce the burden on health systems.
The company has also mentioned its first major collaborations with Parexel and Fortrea, which will allow Evinova’s digital health solutions to be offered to their wide customer base. AstraZeneca’s Chief Executive, Pascal Soriot, has expressed confidence in Evinova’s potential to fundamentally improve patient care, drive healthcare transformation, and reduce carbon emissions.
This strategic initiative is aimed at applying scientific expertise and track record in developing AI-enabled digital technologies at scale to benefit patient care. For more information, contact Michael Susin at email@example.com.